(12) United States Patent (10) Patent No.: US 8,551.496 B2 Gokaraju Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US008551.496 B2 (12) United States Patent (10) Patent No.: US 8,551.496 B2 Gokaraju et al. (45) Date of Patent: Oct. 8, 2013 (54) BOSWELLIA LOW POLAR GUM RESIN OTHER PUBLICATIONS EXTRACT AND ITS SYNERGISTC COMPOSITIONS Kasali et al. (2002) Flavour Fragr. J. 17:462-464.* Krohnet al. (2001) Phytochem. Anal. 12:374-376.* (75) Inventors: Ganga Raju Gokaraju, Vijayawada Mahajan et al. (1995) Phytochemistry, vol.39, No. 2, pp. 453-455.* Ammon (2006) Planta Medical Natural Products and Medicinal (IN); Rama Raju Gokaraju, Plant Research 72.12 (2006): 1100-11 16.* Vijayawada (IN); Ventaka Kanaka Chevrier et al. (2005) Clin. Diagn. Lab. Immunol. 12(5): 575-580.* Ranga Raju Gokaraju, Vijayawada Houssen et al. (2010) Clinical Biochemistry 43: 887-890.* (IN); Trimurtulu Golakoti, Vijayawada Baser, S. Chemical Investigations on Boswellia Species, University (IN); Kiran Bhupathiraju, Vijayawada of Hamburg (online), Mar. 18, 2005, pp. 1-256, retrieved from the (IN) Internet: (http://www.boswellness.com/sites/default/files/pdfs/Dis SertationBasar.pdf) on Aug. 10, 2012. (73) Assignee: Laila Nutraceuticals, Vijayawada (IN) Al-Harrasi et al., Phytochemical Analysis of the Essential Oil from Botanically Certified Oleogum Resin of Boswellia sacra (Omani (*) Notice: Subject to any disclaimer, the term of this Luban), Molecules. Sep. 16, 2008. vol. 13, No. 9, pp. 218 1-2 189. patent is extended or adjusted under 35 Ehrman et al., Phytochemical Databases of Chinese Herbal Constitu U.S.C. 154(b) by 0 days. ents and Bioactive Plant Compounds with Known Target Specifici ties. Journal of Chemical Information and Modelling, Jan. 9, 2007. (21) Appl. No.: 13/584,099 vol. 47, No. 2, pp. 254-263. Cuaz-Perolin et al., Antiinflammatory and Antiatherogenic Effects of (22) Filed: Aug. 13, 2012 the NF-kB Inhibitor Acetyl-11-Keto-B-Boswellic Acid in LPS-Chal lenged ApoE / Mice, Arterioscler Thromb Vasc Biol. 2008; (65) Prior Publication Data 28:272-277. Kimmatkar et al., Efficacy and tolerability of Boswellia serrata US 2012/O3O1432 A1 Nov. 29, 2012 extract in treatment of osteoarthritis of knee-A randomized double blind placebo controlled trial. Phytomedicine 10: 3-7 (2003). Related U.S. Application Data Ernst, Frankincense:systematic review, BMJ 2008; 337:a2813. (63) Continuation-in-part of application No. Safayhi et al., Inhibition by Boswellic Acids of Huma Leukocyte PCT/IN2010/000233, filed on Apr. 12, 2010. Elastase, Journal of Pharmacology and Experimental Therapeutics 281:460-463. 1997. (30) Foreign Application Priority Data Sailer et al., Acetyl-11-keto-B-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Feb. 15, 2010 (IN) ............................. 384f CHEA2010 British Journal of Pharmacology. (1996) 117,615-618. International Search Report dated for PCT/IN2010/000233 dated (51) Int. Cl. Oct. 5, 2010. A6 IK3I/00 (2006.01) A6 IK35/00 (2006.01) * cited by examiner A6 IK36/00 (2006.01) A6 IK36/906 (2006.01) Primary Examiner — Chris R Tate (52) U.S. Cl. Assistant Examiner — Russell Fiebig USPC ....................... 424/195.18; 424/725; 424/756 (74) Attorney, Agent, or Firm — Kramer Amado, P.C. (58) Field of Classification Search None (57) ABSTRACT See application file for complete search history. The present disclosure describes Boswellia low polar gum resin extract (BLPRE) comprising novel phytochemical com (56) References Cited position of sesquiterpenes, diterpenes, triterpenes and other phytochemical(s) obtained from gum resin of Boswellia spe U.S. PATENT DOCUMENTS cies. The present disclosure also describes compositions 5,629.351 A * 5/1997 Taneja et al. .................. 514,765 comprising BLPRE in combination with one or more com 6,589,516 B1* 7/2003 Eyre et al. .................... 424.70.1 2004/0202709 A1 10/2004 Kirby et al. ponent(s) selected from biologically active ingredient(s), 2005/0282772 A1* 12/2005 Gokaraju et al. ............... 514/54 functional ingredient(s), excipient(s), diluents(s), carrier(s) 2006,0040000 A1 2/2006 Gokaraju et al. and additive(s) or mixtures thereof. Further the present dis 2006, OO62859 A1 3, 2006 Blum et al. closure also provides synergistic composition(s) comprising 2006/0280811 A1 12/2006 Bombardelli 2007/0281045 A1 12/2007 Tripp et al. Boswellia low polar gum resin extract (BLPRE) and at least 2008/0275117 A1 11, 2008 Li et al. one component selected from but not limited to extract(s), 2008/0317885 A1 12, 2008 Baker fraction(s), phytochemical(s) or their salts or mixtures thereof derived from Boswellia species or Curcuma species. FOREIGN PATENT DOCUMENTS WO O215916 2, 2002 28 Claims, 4 Drawing Sheets U.S. Patent Oct. 8, 2013 Sheet 1 of 4 US 8,551.496 B2 FIG. 1 Oh 2 R = OH and R = H 3 R = H and R = OH s 4. 2. U.S. Patent Oct. 8, 2013 Sheet 2 of 4 US 8.551.496 B2 FIG. 2 600 2.00 4.00. 6.00 800 1000 12.00 400 16.00 1800 2000 2200 24.00 2600 2800 3000 3200 34.00 36.00 38.00 4000 42.00 Minutes A: chromatogram at 252 mm 0.0. M 0. e 0.0 Lux S s n w 0.05 r se st ce - o s co s A /\ 0.00 W AA A Sya -0.05 20 4.00 so 8.00 10.00 1200 1400 1so 18.0 2000 2200 24.00 26.00 2ao 30.00 o 3400 38.00 38.00 40.00 Minutes B: chromatogram at 210 nm U.S. Patent Oct. 8, 2013 Sheet 3 of 4 US 8,551.496 B2 FIG 3 5-LOX inhibition at 10 g/ml BSLPRE BCLPRE BSE 85% BCE 85% BSE 55% Composition-3A Composition-4 Composition-18 Composition-7A U.S. Patent Oct. 8, 2013 Sheet 4 of 4 US 8,551.496 B2 FIG. 4 % reduct ion in paw e dema % reduction in paw edema US 8,551.496 B2 1. 2 BOSWELLIA LOW POLAR GUMI RESN (AKBA) is biologically the most active component among its EXTRACT AND ITS SYNERGISTC congeners, with an ICs of 1.5 uM for the inhibition of COMPOSITIONS 5-LOX. There is, however, no known prior art relating to Boswellia CROSS-REFERENCE TO APPLICATIONS 5 low polar gum resin extract (BLPRE) comprising a phy tochemical composition of Sesquiterpenes, diterpenes, and This application is a continuation-in-part of international triterpenes or compositions thereof, for the prevention, con application PCT/IN2010/000233, published as WO 2011/ trol and treatment of disorders or diseases in warm blooded 099029, filed on Apr. 12, 2010. The entire disclosures of animals. international application PCT/IN2010/000233 is hereby 10 incorporated by reference in their entirety. SUMMARY FIELD OF THE DISCLOSURE In an important aspect, the present disclosure provides a Boswellia low polar gum resin extract (BLPRE) comprising The present disclosure provides Boswellia low polar gum 15 novel phytochemical composition of sesquiterpenes, diterpe resin extract (BLPRE) comprising novel phytochemical com nes, triterpenes and other phytochemical(s) obtained from the position(s) of sesquiterpenes, diterpenes, triterpenes and gum resin of Boswellia species. other phytochemical(s) obtained from gum resin of Boswellia Another aspect of the disclosure is to provide composi species. tion(s) comprising Boswellia low polar gum resin extract The disclosure also provides compositions comprising (BLPRE) in combination with at least one component Boswellia low polar gum resin extract (BLPRE) and at least selected from biologically active ingredient(s), functional one component selected from biologically active ingre ingredient(s), excipient(s), diluents(s), carrier(s) and additi dient(s), functional ingredient(s), excipient(s), diluents(s). ve(s) or mixtures thereof. carrier(s) and additive(s) or mixtures thereof. Another major aspect of the present disclosure is to provide Further the disclosure also provides Synergistic composi 25 synergistic composition(s) comprising Boswellia low polar tion(s) comprising Boswellia low polar gum resin extract gum resin extract (BLPRE) in combination with at least one (BLPRE) and at least one component selected from ex component selected from polar extracts orphytochemicals, or tract(s), fraction(s), phytochemical(s) and their salts or mix their salts or mixtures, where the polar extracts or phy tures thereof derived from Boswellia species or Curcuma tochemicals are derived from Boswellia species. species. 30 Another aspect of the present disclosure is to provide Syn ergistic composition(s) comprising Boswellia low polar gum BACKGROUND resin extract (BLPRE) and at least one component selected from the extract(s), fraction(s), phytochemical(s) and their There are numerous pharmaceutical, herbal ingredient(s) salts or mixtures thereof derived from Curcuma species. and biologically active molecules that are effective invitro for 35 Another aspect of the disclosure is to provide synergistic a disease or disorder. However, several of them are not effec composition(s) of Boswellia low polar gum resin extract (BL tive or not bioavailable in vivo (warm blooded animals). It is PRE) with at least one component selected from but not thus important to explore, identify and invent safe and effec limited to biologically active ingredient(s), functional ingre tive compound(s) or composition(s) that helps increase the in dient(s) or mixtures thereof. Vivo activity of Such pharmaceutical or herbal ingredient(s) 40 Another aspect of the disclosure is to provide Boswellia through synergism. In this process the inventors have low polar gum resin extract (BLPRE) comprising a novel screened a number of extracts, fractions, phytochemical(s) phytochemical composition and its compositions for use in and compound(s) originating from plants, animals and micro warm blooded animal(s) in need thereof. organisms; individually and in combinations. Various embodiments disclosed herein relate to a The gum resin of Boswellia has been very widely used 45 Boswellia low polar gum resin extract (BLPRE) comprising a since ancient times.